ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Добро vs Зло

Добро vs Зло

Авторы:
Юлия Юрьевна Грабовецкая

Журнал: Non nocere. Новый терапевтический журнал. 2025;(12):42-46.

Прочитано: 298 раз

Резюме

ГКС в клинической практике: польза и риск.

Дата публикации: 30.12.2025

Литература / References
  1. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab. 2024 Jun 17;109(7):1657-1683. https://doi.org/10.1210/clinem/dgae250
  2. Ingrasciotta Y, Jin Y, Foti SS, et al. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study. Clin Rheumatol. 2023 Apr;42(4):1047-1059. https://doi.org/10.1007/s10067-022-06478-4
  3. Berardicurti O, Ruscitti P, Pavlych V, Conforti A, Giacomelli R, Cipriani P. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. Expert Rev Clin Pharmacol. 2020 Jun;13(6):593-604. https://doi.org/10.1080/17512433.2020.1772055
  4. Hysa E, Vojinovic T, Gotelli E, et al. The dichotomy of glucocorticosteroid treatment in immune-inflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice. Reumatologia. 2023;61(4):283-293. https://doi.org/10.5114/reum/170845
  5. Keyßer G. Sicherheitsaspekte der Therapie mit Glukokortikoiden bei rheumatoider Arthritis [Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis]. Z Rheumatol. 2021 May;80(4):295-304. German. https://doi.org/10.1007/s00393-021-00972-x
  6. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010 Sep;69(9):1629-1635. https://doi.org/10.1136/ard.2009.119933
  7. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35-45. https://doi.org/10.1002/art.10697
  8. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 Sep 15;353(11):1114-1123. https://doi.org/10.1056/NEJMoa050524
  9. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008 Mar 22;371(9617):987-997. https://doi.org/10.1016/S0140-6736(08)60453-5
  10. Van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013 Mar;65(3):559-570. https://doi.org/10.1002/art.37816
  11. Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. https://doi.org/10.1056/NEJMoa2201302
  12. Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. https://doi.org/10.1002/art.41032
  13. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 2015 Jun;67(6):1424-1437. https://doi.org/10.1002/art.39093
  14. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009 Aug;60(8):2272-2283. https://doi.org/10.1002/art.24638
  15. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 Apr;69(4):631-637. https://doi.org/10.1136/ard.2009.123919
  16. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. https://doi.org/10.1002/acr.24596
  17. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. https://doi.org/10.1136/ard-2022-223356
  18. Рубрикатор клинических рекомендаций. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Ревматоидный артрит [Электронный ресурс]. Год утверждения: 2024. ID: 250_3. Дата обращения: 18.10.2025. https://cr.minzdrav.gov.ru/view-cr/250_3
  19. Xie W, Huang H, Geng Y, Fan Y, Zhang Z. Current practice, trends and attitudes of rheumatologists towards glucocorticoids use for rheumatoid arthritis (GURANTEE): a national cross-sectional survey across China. Rheumatol Int. 2024 Nov;44(11):2473-2482. https://doi.org/10.1007/s00296-024-05713-2
  20. George MD, Baker JF, Wallace B, et al. Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids. Arthritis Care Res (Hoboken). 2021 Nov;73(11):1597-1605. https://doi.org/10.1002/acr.24382
  21. Wallace BI, Moore MN, Heisler AC, et al. Fibromyalgianess and glucocorticoid persistence among patients with rheumatoid arthritis. Rheumatology (Oxford). 2022 Apr 11;61(4):1556-1562. https://doi.org/10.1093/rheumatology/keab583
  22. McWilliams DF, Thankaraj D, Jones-Diette J, et al. The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2021 Dec 24;61(1):76-89. https://doi.org/10.1093/rheumatology/keab503
  23. Xie W, Huang H, Zhang Z. Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience. Rheumatol Ther. 2023 Apr;10(2):405-419. https://doi.org/10.1007/s40744-022-00527-9
  24. Xie W, Huang H, Zhang Z. Prediction of flare following glucocorticoids withdrawal in rheumatoid arthritis patients with continuation of csDMARDs: a real-life study. Intern Emerg Med. 2023 Sep;18(6):1759-1767. https://doi.org/10.1007/s11739-023-03362-0
  25. Wallace BI, England BR, Baker JF, et al. Lowering Expectations: Glucocorticoid Tapering Among Veterans With Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy. ACR Open Rheumatol. 2023 Sep;5(9):437-442. https://doi.org/10.1002/acr2.11584
  26. Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. Eur J Endocrinol. 2024 May 2;190(5):G25–G51. https://doi.org/10.1093/ejendo/lvae029
  27. Filippa MG, Tektonidou MG, Mantzou A, et al. Adrenocortical dysfunction in rheumatoid arthritis: Α narrative review and future directions. Eur J Clin Invest. 2022 Jan;52(1):e13635. https://doi.org/10.1111/eci.13635
slide-cover
slide-cover
slide-cover
slide-cover
Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29

  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12

  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru

  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026